Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply
- PMID: 36858725
- DOI: 10.1016/S1470-2045(23)00065-7
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply
Conflict of interest statement
SRDJ declares research funding from Pfizer, Puma, Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche–Genetech; consulting fees from Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, Sanofi, Genzyme; and speakers’ bureau fees from Pfizer, Eisai, AstraZeneca, Roche–Genetech. VA owns stock and is an employee of Eli Lilly.
Comment on
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Free PMC article. Clinical Trial.
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.Lancet Oncol. 2023 Mar;24(3):e103. doi: 10.1016/S1470-2045(23)00014-1. Lancet Oncol. 2023. PMID: 36858724 No abstract available.
Similar articles
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.Lancet Oncol. 2023 Mar;24(3):e103. doi: 10.1016/S1470-2045(23)00014-1. Lancet Oncol. 2023. PMID: 36858724 No abstract available.
-
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2. Breast Cancer Res. 2021. PMID: 34425869 Free PMC article. Clinical Trial.
-
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782. JAMA Oncol. 2020. PMID: 31563959 Free PMC article. Clinical Trial.
-
[Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].Gan To Kagaku Ryoho. 2021 Dec;48(12):1475-1483. Gan To Kagaku Ryoho. 2021. PMID: 34911915 Review. Japanese.
-
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.Future Oncol. 2020 Nov;16(33):2763-2778. doi: 10.2217/fon-2020-0604. Epub 2020 Aug 12. Future Oncol. 2020. PMID: 32781837 Review.
Cited by
-
Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):653-663. doi: 10.1055/a-2074-0551. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37916183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous